Literature DB >> 18052942

Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men.

Donald J Brambilla1, Amy B O'Donnell, Alvin M Matsumoto, John B McKinlay.   

Abstract

BACKGROUND: Estimates of intraindividual variation in hormone levels provide the basis for interpreting hormone measurements clinically and for developing eligibility criteria for trials of hormone replacement therapy. However, reliable systematic estimates of such variation are lacking.
OBJECTIVE: To estimate intraindividual variation of serum total, free and bioavailable testosterone (T), dihydrotestosterone (DHT), SHBG, LH, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulphate (DHEAS), oestrone, oestradiol and cortisol, and the contributions of biological and assay variation to the total.
DESIGN: Paired blood samples were obtained 1-3 days apart at entry and again 3 months and 6 months later (maximum six samples per subject). Each sample consisted of a pool of equal aliquots of two blood draws 20 min apart. STUDY PARTICIPANTS: Men aged 30-79 years were randomly selected from the respondents to the Boston Area Community Health Survey, a study of the health of the general population of Boston, MA, USA. Analysis was based on 132 men, including 121 who completed all six visits, 8 who completed the first two visits and 3 who completed the first four visits. MEASUREMENTS: Day-to-day and 3-month (long-term) intraindividual standard deviations, after transforming measurements to logarithms to eliminate the contribution of hormone level to intraindividual variation.
RESULTS: Biological variation generally accounted for more of total intraindividual variation than did assay variation. Day-to-day biological variation accounted for more of the total than did long-term biological variation. Short-term variability was greater in hormones with pulsatile secretion (e.g. LH) than those that exhibit less ultradian variation. Depending on the hormone, the intraindividual standard deviations imply that a clinician can expect to see a difference exceeding 18-28% about half the time when two measurements are made on a subject. The difference will exceed 27-54% about a quarter of the time.
CONCLUSIONS: Given the level of intraindividual variability in hormone levels found in this study, one sample is generally not sufficient to characterize an individual's hormone levels but collecting more than three is probably not warranted. This is true for clinical measurements and for hormone measurements used to determine eligibility for a clinical trial of hormone replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052942     DOI: 10.1111/j.1365-2265.2007.02976.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  41 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010.

Authors:  Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Holly M Holmes; Mukaila A Raji; Abraham Morgentaler; Bret T Howrey; Yu-Li Lin; Kenneth J Ottenbacher
Journal:  Public Health Rep       Date:  2015 Mar-Apr       Impact factor: 2.792

3.  Recruitment and Screening for the Testosterone Trials.

Authors:  Jane A Cauley; Laura Fluharty; Susan S Ellenberg; Thomas M Gill; Kristine E Ensrud; Elizabeth Barrett-Connor; Denise Cifelli; Glenn R Cunningham; Alvin M Matsumoto; Shalender Bhasin; Marco Pahor; John T Farrar; David Cella; Raymond C Rosen; Susan M Resnick; Ronald S Swerdloff; Cora E Lewis; Mark E Molitch; Jill P Crandall; Alisa J Stephens-Shields; Thomas W Strorer; Christina Wang; Stephen Anton; Shehzad Basaria; Susan Diem; Vafa Tabatabaie; Darlene Dougar; Xiaoling Hou; Peter J Snyder
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2015-04-15       Impact factor: 6.053

4.  Hypogonadism: Easy to define, hard to diagnose, and controversial to treat.

Authors:  Joshua Sterling; Aaron M Bernie; Ranjith Ramasamy
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 5.  Aging and sex hormones in males.

Authors:  Maria Chiara Decaroli; Vincenzo Rochira
Journal:  Virulence       Date:  2016-11-10       Impact factor: 5.882

Review 6.  Alternative treatment modalities for the hypogonadal patient.

Authors:  Landon W Trost; Mohit Khera
Journal:  Curr Urol Rep       Date:  2014-07       Impact factor: 3.092

7.  The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission.

Authors:  Thomas G Travison; Rebecca Shackelton; Andre B Araujo; Susan A Hall; Rachel E Williams; Richard V Clark; Amy B O'Donnell; John B McKinlay
Journal:  J Am Geriatr Soc       Date:  2008-05       Impact factor: 5.562

8.  Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Authors:  Andrew J Weickhardt; Robert C Doebele; W Thomas Purcell; Paul A Bunn; Ana B Oton; Micol S Rothman; Margaret E Wierman; Tony Mok; Sanjay Popat; Julie Bauman; Jorge Nieva; Silvia Novello; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

9.  Cohort profile: the Boston Area Community Health (BACH) survey.

Authors:  Rebecca S Piccolo; Andre B Araujo; Neil Pearce; John B McKinlay
Journal:  Int J Epidemiol       Date:  2012-12-05       Impact factor: 7.196

10.  The safety and efficacy of clomiphene citrate in hypoandrogenic and subfertile men.

Authors:  D P Patel; W O Brant; J B Myers; A P Presson; E B Johnstone; J A Dorais; K I Aston; D T Carrell; J M Hotaling
Journal:  Int J Impot Res       Date:  2015-08-20       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.